QDEL
HealthcareQuidelOrtho Corporation
$30.06
+$1.28 (+4.45%)
Jan 5, 2026
Price History (1Y)
Analysis
QuidelOrtho Corporation operates within the Healthcare sector and Medical Devices industry. With a market capitalization of $2.04 billion, revenue of $2.71 billion (TTM), and approximately 6,600 employees, it is a significant player in its field. The company's financial health reveals mixed results. Gross Margin stands at 47.2%, while Operating Margin is significantly lower at 6.7%. Profit Margin is negative at -43.5%. On the other hand, Return on Equity (ROE) and Return on Assets (ROA) are -45.2% and 1.4%, respectively. The balance sheet indicates a substantial debt of $2.87 billion and cash reserves of $99 million. QuidelOrtho Corporation's valuation metrics show a Forward P/E ratio of 11.86, an EV/EBITDA of 8.17, and a Price to Book ratio of 1.00. Revenue Growth (YoY) is -3.7%. The company does not pay dividends.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About QuidelOrtho Corporation
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $2.04B
- P/E Ratio
- N/A
- 52-Week High
- $49.45
- 52-Week Low
- $19.50
- Avg Volume
- 1.24M
- Beta
- 0.59
Company Info
- Industry
- Medical Devices
- Exchange
- NMS
- Country
- United States
- Employees
- 6,600